Methylergonovine and Carboprost Equally Effective for Refractory Uterine Atony, finds research

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-01-06 15:00 GMT   |   Update On 2025-01-07 07:03 GMT

Researchers have identified that methylergonovine maleate and carboprost tromethamine are equivalent in managing refractory uterine atony during cesarean delivery. A new double-blind randomized trial recently performed at two large academic perinatal centers showed that neither agent differed significantly from the other in uterine tone scores 10 minutes after administration. The study was conducted by Cole N. and colleagues which was published in the journal Obstetrics & Gynecology.

Uterine atony is the most common cause of postpartum hemorrhage (PPH), accounting for the majority of maternal morbidity and mortality. Therefore, comparative efficacy and safety studies of the second-line uterotonics commonly administered would be valuable in guiding clinical decisions in obstetric care.

The patients were those with non-emergency cesarean delivery with uterine atony refractory to oxytocin and were randomly assigned intraoperatively to receive a single intramuscular dose of either methylergonovine or carboprost. The main outcome was uterine tone score on a 0–10 numeric rating scale assessed by blinded obstetricians 10 minutes after drug administration.

Secondary outcomes were uterine tone at 5 minutes, requirement for additional uterotonic, blood loss, interventions for uterine atony, postpartum hematocrit change, transfusions, adverse drug reactions, and length of hospitalization. A total number of 50 subjects in each group were calculated to have a 1-point difference on uterine tone scores with 80% power and a two-sided α of 0.05.

Key Findings

Primary Outcome:

• Mean uterine tone scores at 10 minutes:

• Methylergonovine: 7.3±1.7

• Carboprost: 7.6±2.1

• Adjusted mean difference: −0.1 (95% CI, −0.8 to 0.6, p=0.76).

Other Uterotonic Use:

• Methylergonovine arm: 30.0% needed additional uterotonic.

• Carboprost arm: 34.0% needed additional uterotonic.

• AOR: 0.72 (95% CI, 0.27–1.89, p=0.505).

Bleeding:

Geometric mean quantitative blood loss,

• Methylergonovine: 756 mL (95% CI, 636–898).

• Carboprost: 708 mL (95% CI, 619–810).

• Adjustive ratio of geometric mean: 1.06 (95% CI, 0.86–1.31, p=0.588).

Other intervention and safety:

• There was no significant variation in the other interventions with uterine atony or postpartum hemorrhage.

• No notable drug or transfusion reactions.

The study concluded that there is no difference in uterine tone scores or secondary outcomes between methylergonovine and carboprost for refractory uterine atony. The results support the use of either agent as an acceptable second-line uterotonic, offering flexibility and efficacy in managing this critical obstetric condition.

Reference:

Cole, N. M., Kim, J. J., Lumbreras-Marquez, M. I., Fields, K. G., Mendez-Pino, L., Farber, M. K., Carusi, D. A., Toledo, P., & Bateman, B. T. (2024). Second-line uterotonics for uterine atony: A randomized controlled trial. Obstetrics and Gynecology, 144(6), 832. https://doi.org/10.1097/aog.0000000000005744

Tags:    
Article Source : Obstetrics & Gynecology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News